Scenic Biotech B.V.. (11/30/17). "Press Release: Scenic Appoints Alexandra Glucksmann as Member of its Board of Directors".

	Organisation	Scenic Biotech B.V.
	Organisation 2	Cedilla Therapeutics Inc.
	Product	small-molecule drug to modulate DNA/RNA
	Product 2	BIOTECH

Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Alexandra Glucksmann to its Board of Directors.

Alexandra holds a Ph.D. with honors from the University of Chicago and was a post-doctoral fellow at the M.I.T.. She spent 13 years at Millennium Pharmaceuticals, ultimately serving as Vice President. She was Senior VP at Cerulean Pharma. Most recently, Alexandra served as founding chief operating officer of Editas Medicine Inc.. Alexandra is currently President and CEO at Cedilla Therapeutics and serves on the board of Women in the Enterprise of Science and Technology (WEST).

Record changed: 2020-06-26

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Scenic Biotech B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]